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Aims: Cardiac glycosides have been extensively used in the treatment of congestive heart failure for more than
200 years. Recently, cardenolides and bufadienolides were isolated from mammalian tissue and are
considered as a new class of steroidal hormones. The aim of the present work was to characterize the
interaction between the most clinical used cardiac glycoside digoxin and the cardiac glycosides known to
exist endogenously, i.e., ouabain, marinobufagin and telocinobufagin, on human kidney Na+/K+-ATPase.
Main methods: Inhibition of Na+/K+-ATPase activity from crude membrane preparations of human kidney
was performed using increasing concentrations of the drugs alone or mixtures of ouabain:digoxin,
telocinobufagin:digoxin and marinobufagin:digoxin in a ﬁxed ratio 1:4, 2:3 and 3:2, respectively. The
colorimetric method of Fiske and Subbarow was used to measure the inorganic phosphate released.
Key ﬁndings: Analyses of inhibition curves showed that the experimental curves for all combinations were
superimposed on the theoretical additive curves indicating that an additive effect occurs among distinct
cardenolides and bufadienolides combinations on the human α1β1 Na+/K+-ATPase protomer.
Signiﬁcance: Considering the extensive use of digoxin in the treatment of heart failure and the recent ﬁndings
that endogenous cardiac glycosides may have altered levels in many diseases, including heart failure, the
demonstration of additive effect between cardiac glycosides can help in the understanding of recent clinical
observations, including that lower than usual doses of cardiac glycosides are necessary for decreasing
mortality in these patients.
© 2010 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Cardiac glycosides have been widely used in the treatment of
congestive heart failure for more than 200 years due to its positive
inotropic effect and beneﬁts on hemodynamics (Hauptman and Kelly,
1999).However, themolecularmechanismof thesedrugs emerged only
in 1963, when Repke and Portius (1963) described the Na+/K+-ATPase
as their binding target. In heart failure treatment, themost used cardiac
glycoside is digoxin, a cardenolide isolated from plants of the genus
Digitalis. However, a wide diversity of cardenolides has been identiﬁed
in other plant families (Mijatovic et al., 2007). Furthermore, structurally
related steroids, i.e. bufadienolides, have also been identiﬁed in
amphibians, snakes and ﬁreﬂies (Eisner et al., 1978; Steyn andHeerden,
1998; Daly et al., 2004; Hutchinson et al., 2007) and differ from plant
cardenolides due to the presence of a six-membered, instead of a ﬁve-+55 21 25626659.
evier OA license.membered lactone ring at the C-17 position of the steroid nucleus (Flier
et al., 1980; Mijatovic et al., 2007). In 1991, a cardiac glycoside
indistinguishable from ouabain was isolated from human plasma
(Hamlyn et al., 1991). Afterwards, other cardenolides and also
bufadienolides have been isolated from humans and other mammals
(Hamlyn andManunta, 1992; Lichtstein et al., 1993; Bagrov et al., 1998;
Komiyama et al., 2005). They are now considered a new class of
mammalian steroidal hormones, but their importance and even their
existence have still been a matter of controversy (Bagrov et al., 2009;
Nicholls et al., 2009). Nevertheless, the increase of the plasma titer of
cardiotonic steroids in several animal models and human disease states
(Ferrandi et al., 2005; Schoner and Scheiner-Bobis, 2007) as well as the
discovery of novel Na+/K+-ATPase signaling functions (Xie and Askari,
2002) give strong support for the (patho)physiological relevance of
these cardiac glycosides. Besides, their presence may have implications
in current therapies since interactions at the molecular level could
happen between endogenous molecules acting in the same receptor/
binding site of the drug administered for the treatment of congestive
heart failure. It is important to note that patients on digoxin therapy
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suggesting that endogenous ouabain may contribute to digoxin toxicity
(Manunta and Ferrandi, 2006).
Despite the vast literature dedicated to theoretical and experimental
aspects of synergism, few works are concerned with drugs that act on
the samemolecular target. This kind of interaction is not easy to predict
since binding to the same receptor might result in simple competition
but also in conformational changes that could lead to synergism or
antagonism (Bell, 2005).
Recently, we described that ouabain can act synergistically with
8-methoxycoumestrol on the rat kidney enzyme (Pôças et al., 2007).
The present study was designed to characterize the interaction
between digoxin, the cardiac glycoside extensively used in the
therapeutics of congestive heart failure and also considered as an
endogenous steroid, and endogenous cardenolide (ouabain) and
bufadienolides (telocinobufagin andmarinobufagin) in human kidney
Na+/K+-ATPase activity. Our results show that endogenous cardiac
glycosides have an additive effect on human Na+/K+-ATPase
inhibition by digoxin and the possible consequences are discussed.
Materials and methods
Drugs
The bufadienolides telocinobufagin and marinobufagin were
isolated from the Brazilian toad Rhinella schneideri parotoid glands
secretion by chromatographic separation on neutral aluminum oxide
column and chemically characterized by spectrometric data, as
previously described (Cunha-Filho et al., 2010). Digoxin and ouabain
were obtained from Sigma-Aldrich (USA).
Preparation of Na+/K+-ATPase from human kidney
Normal human renal tissue specimens (from the unaffected pole)
were obtained from patients who underwent unilateral nephrectomy
due to well-encapsulated hypernephroma in one kidney pole. All
procedures for the use of discarded organ portions were done in
accordance to the Institutional Ethical Committee from Hospital
Universitário Clementino Fraga Filho, Universidade Federal do Rio de
Janeiro, Brazil.
Crude homogenate preparations were obtained as previously
described (Quintas et al., 1997; Lopez et al., 2002). Brieﬂy, the tissue
was homogenized in a Potter homogenizer with a motor driven Teﬂon
pestle at 4 °C in 2–3 volumes of ice cold 0.25 M buffered sucrose pH
7.4, containing 0.1 mM phenylmethylsulfonyl ﬂuoride (PMSF) per
gram organ. After centrifugation at 100 000 g for 1 h, pellets were
resuspended with the same buffer but PMSF and were stored in N2
until use. The protein concentration was measured according to the
method of Lowry et al. (1951) using bovine serum albumin as the
standard.
Inhibition of Na+/K+-ATPase activity
The Na+/K+-ATPase activity was determined by the Fiske and
Subbarow method (1925) with slight modiﬁcations, as described
(Pôças et al., 2007). The speciﬁc activity of the enzyme corresponds to
the difference between the total ATPase activity and the activity
measured in the presence of 1 mM ouabain. The preparation was
incubated at 37 °C for 2 h, in a total volume of 0.5 mL. The incubation
was performed in the presence of 84 mM NaCl, 3 mM KCl, 3 mM
MgCl2, 1.2 mM ATPNa2, 2.5 mM EGTA, 10 mM sodium azide and
20 mM maleic acid buffered to pH 7.4 with Tris in the absence or
presence of inhibitor(s). Classical concentration–effect curves were
performedwith each of the four inhibitors, alone. For the construction
of the combination curves, we used increasing concentrations of the
mixtures ouabain:digoxin in the ﬁxed ratio 1:4, telocinobufagin:digoxin in the ﬁxed ratio 2:3 or marinobufagin:digoxin in the ﬁxed
ratio 3:2. These ratios were calculated according to the method
proposed by Tallarida et al. (1997).
Statistical analysis
Inhibition curves
Inhibition curves were ﬁtted using computerized non-linear
regression analysis of the data (Prism®, GraphPad Software Inc.,
version 4.00), assuming a sigmoidal dose–response curve model,
where the parameters bottom and top were ﬁxed at 0 and 100%
inhibition, respectively, as previously reported for a similar study
(Pôças et al., 2007).
Comparison of the composite additive and mixture regression curves
The IC50 of the calculated (theoretical) additive curvewas obtained
by non-linear regression analysis of the theoretical curve constructed
considering the theoretical effects calculated for different concentra-
tions of the mixture according to the method of Tallarida et al. (1997),
as we reported previously (Pôças et al., 2007).
Isobolographic analysis
For the classical isobolographic analysis, we selected 50% inhibi-
tion as the effect level. The experimental combination curves were
used to determine the (empirical) pair of drug concentrations eliciting
50% inhibition (E) and their limits of conﬁdence. The theoretical pair
of concentrations of the mixture of two drugs at the predetermined
ﬁxed ratio that should elicit 50% inhibition if the effect was additive
(T), was calculated according to equation 11 described by Tallarida et
al. (1997). The concentration of each drug in this mixture (T) was then
compared to the experimental combination (E), by a suitable t test
(Tallarida et al., 1997).
Results
The inhibition curves of Na+/K+-ATPase from human kidney (that
has only one isozyme, α1β1) by the combination of different
cardenolides and bufadienolides are shown in Fig. 1. As described in
Table 1, the IC50 values for ouabain and digoxin (Hauck et al., 2009)
and marinobufagin (Katz et al., 2010) are in very good accordance to
the values described in recent binding studies using expressed human
α1β1 isoform. As far as we know, this is the ﬁrst description of human
Na+/K+-ATPase inhibition by telocinobufagin. The mixture (experi-
mental) curves for these combinations were constructed using the
proportion 1:4 (ouabain:digoxin) or 2:3 (telocinobufagin:digoxin)
and 3:2 (marinobufagin:digoxin). Fig. 1 shows that these curves are
superimposed on the additive (theoretical) curves, suggesting that
these mixtures of drugs act additively, independently whether
cardenolides or bufadienolides were utilized. The same conclusion
can be achieved analyzing the isobolograms (Fig. 1, inset) where the
experimental pairs of concentrations that achieve 50% inhibitionwere
very close to the additive line.
Discussion
The widespread clinical use of cardiac glycosides, especially
digoxin, for the treatment of congestive heart failure and the discovery
of several endogenous cardiac glycosides in mammals with still barely
known physiological or pathological functions make the investigation
of the effect of different combinations of these compounds on their
well-known molecular target (i.e., Na+/K+-ATPase) an important
topic.
In a previous paper we showed that, differently from the non-
steroidal Na+/K+-ATPase inhibitor 8-methoxycoumestrol, the aglycone
ouabagenin acts additively to ouabain on the rat renal Na+/K+-ATPase
inhibition (Pôças et al., 2007). In thepresentworkwe studied theeffect of
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Fig. 1. Inhibition curves of human kidney Na+,K+-ATPase by (a) ouabain (□), digoxin
(■) and the mixture of both respecting the ﬁxed ratio 1:4 (ouabain:digoxin) (▼).
(b) telocinobufagin (TCB, ▲), digoxin (■) and the experimental mixture of both
respecting the ﬁxed ratio 2:3 (telocinobufagin:digoxin) (▼). (c) marinobufagin (MBG,
●), digoxin (■) and the mixture of both respecting the ﬁxed ratio 3:2 (marinobufagin:
digoxin) (▼). Open triangles (∇) represent the theoretical additive curve for all the
combinations analyzed. Curves were ﬁtted by non-linear regression analysis using the
model of one binding site. Each point represents the mean±SEM from at least three
experiments performed in triplicate. Inset: Isobolographic analyses of the same
mixtures, considering the effect of 50% inhibition. The straight line is the line of
additivity, representing all the additive theoretical combinations giving that level of
inhibition. Point T represents the theoretical pair of concentrations of the mixture of
two drugs at the predetermined ﬁxed ratio that should elicit 50% inhibition if the effect
was additive. Point E denotes the concentration pair that gives the same level of effect,
experimentally. There was no statistical difference between theoretical and experimental
points for all the combinations analyzed (pN0.05).
Table 1
IC50 values for human kidney Na+,K+-ATPase inhibition by different cardiac glycosides
alone and in deﬁned combinations. The proportion of each component in the mixture is
described in brackets. See Materials and methods for the determination of the
theoretical IC50 values for the combinations.
Experimental IC50 (nM) Theoretical IC50 (nM)
Digoxin 289±23 –
Ouabain 63.4±2.9 –
Telocinobufagin 44.2±4.3 –
Marinobufagin 1144±160 –
Ouabain+digoxin (1:4) 172±45 171±2
Telocinobufagin+digoxin (2:3) 117±9 100±0.1
Marinobufagin+digoxin (3:2) 425±37 505±2
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marinobufagin on human renal Na+/K+-ATPase for the following
reasons: (1) digoxin was chosen since it is the main cardiac glycoside
clinically utilized; (2) all of the compounds studied have been identiﬁed
endogenously in man; and, (3) human kidney Na+/K+-ATPase prepa-rationwas chosen in order to be closer to clinical conditions and because
this organ has only the α1β1 isoform, excluding the possibility of
different isoforms with different afﬁnities and interactions that could
interfere with simple combination curves or isobolograms. Our ﬁndings
demonstrate that the inhibitory effect of distinct cardiac glycosides on
human Na+/K+-ATPase is additive. In a certain way, we expected this
behavior since all these compounds are supposed to bind to the same
binding site and conformation of the enzyme, but it is well-known that
predictions for drug combinations are risky unless they are experimen-
tally proved and the existence of synergism as we reported previously
between ouabain and a coumestan could not be ruled out a priori. In
addition, our observations have important therapeutic and physiological
consequences.
Mechanistically, our data are in line with a large body of evidences
indicating that cardiotonic steroids, i.e., substances sharing the same
molecular backbone structure, interact with Na+/K+-ATPase at the
same binding site, composed by a shallow groove of the extracellular
loops between transmembrane segments 1–2 (major binding site), 3–4,
5–6, and 9–10 of the α subunit, stabilizing the E2-P (phosphorylated)
conformation (Pierre and Xie, 2006; Nesher et al., 2007).
In the clinical setting, the Digitalis Investigation Group (DIG) trial,
the largest study of the long-term impact of digoxin therapy on heart
failure patients, concluded that digoxin reduces the frequency of
hospitalizations but had no effect on survival (Digitalis Investigation
Group, 1997). Recent post hoc analyses of DIG data, however, account
that low (from 0.5 up to 0.8 or 0.9 ng/ml) instead of high (≥ 1.0 ng/ml)
serum digoxin levels decrease also mortality rates, revealing a bi-
directional effect (Rathore et al., 2003; Gheorghiade, 2006; Ahmed et al.,
2006, 2007; Ahmed, 2007). Although neurohormonal modulatory
effects (e.g., suppression of sympathetic and renin–angiotensin–
aldosterone systems) are sustained as the key factor responsible for
this beneﬁt, the additive effect of endogenous cardiac glycosides on
digoxin may have a role in counteracting the positive outcome seen at
lower serum digoxin concentrations. Noteworthy, endogenous cardiac
steroids levels are elevated in heart failure (Jortani et al., 2004;Manunta
and Ferrandi, 2006), being suggested as a biomarker for the disease
(Jortani et al., 2004). Furthermore, the disease increases themyocardial
sensitivity to cardiac glycosides probably by bringing Na+/K+-ATPase
expression and activity down (Bundgaard and Kjeldsen, 1996;
Schwinger et al., 1999) and predisposes hypokalemia, a condition that
increases the sensitivity of Na+/K+-ATPase to the cardiac glycosides
(McDonough et al., 1995).
We are aware that inferences from these ﬁndings established in
vitro to in vivo conditions should be done with caution. Ionic
environment, substrate concentration, associated membrane-bound
components and hormonal status along with the action of protein
kinases and phosphatases are notorious modulators of the enzyme
and may affect cardiac glycosides sensitivity (Therien and Blostein,
2000; Bagrov and Shapiro, 2008). Moreover, our observations were
focused on the classical mechanism of cardiac glycosides, i.e., Na+/K+-
ATPase inhibition. The results of cardiac glycosides mixtures on novel
mechanisms, such as signaling transduction through protein–protein
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2007) are unknown. However, as no other cardiac glycosides binding
sites have been determined in Na+/K+-ATPase and these new
mechanisms appear to derive from this interaction, it seems likely
that additivity would occur. Finally, there are other Na+/K+-ATPase
isoforms for the α (α2, α3 and the sperm-speciﬁc α4) and for the β
(β2 and β3) subunits and several protomer arrangements exist.
Unlike what is observed in rodents, though, all the human isoforms
have very similar afﬁnities for cardiac glycosides (Crambert et al.,
2000; Hauck et al., 2009). Thus, we believe that the additional human
isoforms might behave in the same way.
Conclusion
We described the additive effect of cardiac glycosides on the
inhibition of human Na+/K+-ATPase α1β1 isozyme. These results
argue against the possibility of synergistic effect between an
endogenous cardiac glycoside and digoxin during the pharmacolog-
ical treatment of heart failure. The prediction of a therapeutic
relevance from an in vitro study may be premature, but this additive
effect could be one explanation for the decreased mortality observed
only in patients using lower than usual doses of digoxin.
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